Top entities: Rarecells, Patrizia Paterlini, Davide Brechot, Maynooth University, Martin Curley.

What category does this event fall under?

Tech — classified as tech breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Maynooth University recognized Rarecells · Rarecells advances toward milestones

Is this event still developing?

This is an active story, last updated May 14, 2026. Coverage continues to evolve.

Tech tech breakthrough

Rarecells ISET System Recognized

Q: When did this event occur?

First reported May 14, 2026; last updated May 14, 2026.

Q: What is the market impact?

Direct. The recognition of Rarecells' ISET diagnostic system by Maynooth University is expected to positively impact Rarecells' valuation and attract further investment in liquid biopsy technologies.

Analysis based on 6 articles · First reported May 14, 2026 · Last updated May 14, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recognition of Rarecells' ISET diagnostic system by Maynooth University is expected to positively impact Rarecells' valuation and attract further investment in liquid biopsy technologies. This breakthrough could lead to a shift in healthcare systems towards earlier cancer detection, potentially benefiting the broader biotechnology and healthcare sectors.

Biotechnology Healthcare

Event Summary

Rarecells, a liquid biopsy company, announced that its ISET diagnostic system has been recognized by the Innovation Value Institute at Maynooth University as one of the Top 5 Disruptive Health Technologies with the Potential to Change the World. This recognition highlights the ISET technology's ability for low-cost, ultra-sensitive, and highly specific detection of weak cancer signals in blood, supporting earlier cancer detection and broader access to care. Patrizia Paterlini, Founder and CEO of Rarecells, and Davide Brechot, Deputy CEO, emphasized the importance of early detection and the company's position in transforming oncology. Professor Martin Curley of the Innovation Value Institute also praised Rarecells' innovation. The company is advancing towards key milestones, including clinical validation of its AI-powered, multi-omics, multi-cancer early detection (MCED) ISET assay.

Key Actions

100 Maynooth University recognized Rarecells

80 Rarecells advances toward milestones

Entities Involved

oth

Rarecells

Rarecells' ISET diagnostic system was recognized as a top disruptive health technology, enhancing its reputation and potential for future growth in early cancer detection.

Importance 100 Sentiment 70

per

Patrizia Paterlini

Patrizia Paterlini, Founder and CEO of Rarecells, expressed honor for the award, highlighting the company's vision for early cancer detection.

Importance 70 Sentiment 60

per

Davide Brechot

Davide Brechot, Deputy CEO of Rarecells, emphasized the company's unique position in supporting the shift towards preventive healthcare.

Importance 60 Sentiment 50

oth

Maynooth University

Maynooth University, through its Innovation Value Institute, recognized Rarecells' technology, lending credibility to the breakthrough.

Importance 40 Sentiment 10

per

Martin Curley

Martin Curley, Co-Founder of the Innovation Value Institute, commented on the disruptive nature of Rarecells' technology, aligning it with his vision for health transformation.

Importance 30 Sentiment 10

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard